Atara Biotherapeutics (ATRA) risk factors, FY2025 10-K

Atara Biotherapeutics's FY2025 10-K, filed Mar 16, 2026, lists 80 risk factors in 7 groups. Against the prior year's 84: 8 new, 12 dropped, 22 substantially reworded.

Open ATRA in Gloom →
Atara Biotherapeutics' chart, financials and news, free in your browser.Open ATRA in Gloom →
Risk factors listed
807 groups
New this year
8vs 84 last year
Dropped
12since the prior 10-K
Substantially reworded
22of those kept
Section length
39k wordsItem 1A

What the changes say

  • Severe cash shortage with only $8.5 million remaining as of December 31, 2025, threatening operations.
  • Reliance on single approved product Ebvallo and partner Pierre Fabre for commercialization.
  • Ongoing executive departures and staff reductions straining internal financial controls.

What changed since the prior 10-K

New

  • NewRisks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

    protect our rights in our intellectual property and regulatory protections portfolio

    Our commercial revenues from Ebvallo depend on market size, pricing, and our agreement with Pierre Fabre, from whom we may not receive meaningful milestones or royalties for a long time due to the HCRx Agreement.

  • NewRisks Related to the Development of Our Product and Product Candidates

    We have one approved product, Ebvallo, which is currently approved in the European Economic Area (EEA), the UK and Switzerland. If we or our collaborators are unable to successfully develop, manufacture and commercialize tab-cel or experience significant delays in doing so, our business may be materially harmed

    Our business relies heavily on the success of our single approved product, Ebvallo, in the EEA, the UK, and Switzerland.

  • NewRisks Related to Manufacturing

    with the necessary regulatory requirements or may require regulatory approval before selling any products manufactured at that facility. Such an event could delay our clinical studies or reduce our commercial product revenues

    Catastrophic events or failures at our partner's manufacturing facility could cause severe clinical delays and revenue losses that our insurance may not cover.

  • NewRisks Related to Our Intellectual Property

    addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product and product candidates

    Defending our patents against infringement is expensive and risky, and courts could invalidate our patents or find us liable for damages.

  • NewRisks Related to Commercialization of Our Product and Product Candidates

    there may be additional challenges and/or amendments to the ACA. It is unclear how future litigation and the healthcare reform measures of future presidential administrations will impact the ACA and our business

    European pharmaceutical legislation proposals and ACA healthcare reforms could reduce demand and reimbursement for our products.

  • NewRisks Related to Commercialization of Our Product and Product Candidates

    The current presidential administration has also signaled its intent to pursue healthcare reform measures, including

    The White House's Great Healthcare Plan and executive orders signed by President Trump aim to lower drug prices through most-favored-nation pricing and other measures.

  • NewRisks Related to Ownership of Our Common Stock

    reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with

    The departure of CFO Eric Hyllengren and reductions in our finance staff following 2025 layoffs threaten our financial reporting and Sarbanes-Oxley compliance.

  • NewRisks Related to Ownership of Our Common Stock

    claims arising under the Securities Act and, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act

    Our charter designates federal district courts as the exclusive forum for Securities Act claims, which may limit stockholder choice and discourage lawsuits.

Dropped

  • DroppedRisks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

    find suitable commercialization partners who can obtain coverage and adequate reimbursement from third parties, including government payors, set commercially viable prices, market, sell and distribute our approved products

  • DroppedRisks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

    reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product and product candidates

  • DroppedRisks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

    There can be no assurance that we will achieve all of the anticipated benefits of the Fujifilm Transaction and we could face unanticipated challenges

  • DroppedRisks Related to the Development of Our Product and Product Candidates

    If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which could materially harm our business

  • DroppedRisks Related to the Development of Our Product and Product Candidates

    Our business could be adversely affected by health epidemics and pandemics which may present substantial public health and economic challenges around the world

  • DroppedRisks Related to the Development of Our Product and Product Candidates

    Interim “top line” and preliminary data from clinical studies that we or our partners may announce or share with regulatory authorities from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data

    Finding suitable commercialization partners for coverage and reimbursement.

  • DroppedRisks Related to the Development of Our Product and Product Candidates

    data that demonstrate an unacceptable benefit/risk profile, including a lack of efficacy, unforeseen safety issues or adverse side effects

    Estimating actual capital amounts to complete development and commercialization.

  • DroppedRisks Related to the Development of Our Product and Product Candidates

    We may not successfully identify, acquire, develop or commercialize new potential product candidates

  • DroppedRisks Related to Our Dependence on Third Parties

    depend on, among other things, the efforts, allocation of resources, negotiation of pricing and reimbursement and successful commercialization of tab-cel by Pierre Fabre

  • DroppedRisks Related to Our Intellectual Property

    to be unrelated, which may block our efforts or potentially result in any of our product, product candidates or our activities infringing their claims

  • DroppedRisks Related to Commercialization of Our Product and Product Candidates

    able to charge for our future products or the amounts of reimbursement available for our future products from governmental agencies or third-party payors

    Achieving anticipated benefits from the Fujifilm Transaction.

  • DroppedRisks Related to Ownership of Our Common Stock

    If we and our third party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

Reworded

  • 100% rewrittenRisks Related to the Development of Our Product and Product Candidates

    maintaining and growing an organization of scientists and functional experts who can develop our products and technology

    Updated risk heading to focus on recruiting and retaining scientists and functional experts.

  • 73% rewrittenRisks Related to Commercialization of Our Product and Product Candidates

    Current and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of our product candidates and affect the prices for our product and product candidates

    Added specific mention of current and future legislation, unfavorable pricing regulations, and healthcare reform initiatives increasing costs.

  • 64% rewrittenRisks Related to Manufacturing

    If one or more of our partner's CMOs' facilities is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected

    Expanded partner manufacturing risks to explicitly include damage to partner CMO facilities and replacement challenges for us or our partner.

    Was: If one or more of our CMO’s facilities is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected

  • 55% rewrittenRisks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

    the emergence of competing technologies or other adverse market developments

    Replaced financing estimates with a statement that $8.5 million in cash as of December 31, 2025 is insufficient for the next twelve months.

  • 51% rewrittenRisks Related to Ownership of Our Common Stock

    The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities

    Added industry susceptibility to abrupt policy changes due to election cycles and judicial challenges.

    Was: The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updaters and changes in policy priorities

  • 50% rewrittenRisks Related to Manufacturing

    Delays in receiving regulatory approvals for product candidates produced at our partners' CMOs’ facilities could delay our development plans and thereby limit our ability to generate revenues

    Updated to clarify that manufacturing qualification activities occur at our partner's CMOs rather than internal facilities.

    Was: Delays in receiving regulatory approvals for product candidates produced at our CMOs’ facilities could delay our development plans and thereby limit our ability to generate revenues

  • 48% rewrittenRisks Related to Our Intellectual Property

    We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business

    Retained core intellectual property enforcement language regarding third-party infringement and legal proceedings.

  • 44% rewrittenRisks Related to the Development of Our Product and Product Candidates

    Clinical drug development involves a lengthy and expensive process with an uncertain outcome

    Added a specific example noting the FDA placed a clinical hold on tab-cel and ATA3219 INDs in January 2025.

  • 44% rewrittenRisks Related to Our Dependence on Third Parties

    If we, our partner or their CMOs are not able to successfully transfer and produce comparable product and product candidates, our ability to further develop and manufacture our product and product candidates may be negatively impacted

    Was: If we or our CMOs are not able to successfully transfer and produce comparable product and product candidates, our ability to further develop and manufacture our product and product candidates may be negatively impacted

  • 40% rewrittenRisks Related to Our Intellectual Property

    If we are sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our or our partners’ development and commercialization efforts

  • 40% rewrittenRisks Related to Our Dependence on Third Parties

    Maintaining clinical and commercial timelines is dependent on our partner's end-to-end supply chain network to support manufacturing; if we or our partner experience problems with third party suppliers or CMOs, we or our partner may delay development and/or commercialization of our product and product candidates

    Was: Maintaining clinical and commercial timelines is dependent on our end-to-end supply chain network to support manufacturing; if we experience problems with our third party suppliers or CMOs, we may delay development and/or commercialization of our product and product candidates

  • 34% rewrittenRisks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

    Our activities to review and pursue strategic alternatives may not result in a strategic transaction, and even if we do consummate a strategic transaction, there is no assurance that it will deliver the benefits we expect or enhance stockholder value

  • 33% rewrittenRisks Related to the Development of Our Product and Product Candidates

    Our future success is dependent on the marketing authorization of tab-cel

    Was: Our future success is dependent on the marketing authorization of our product candidates

  • 32% rewrittenRisks Related to Ownership of Our Common Stock

    We have incurred and will continue to incur increased costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs

  • 32% rewrittenRisks Related to Ownership of Our Common Stock

    Any of the factors listed above may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management

  • 32% rewrittenRisks Related to the Development of Our Product and Product Candidates

    We may not be able to obtain or maintain orphan drug exclusivity for our product candidates

  • 30% rewrittenRisks Related to the Development of Our Product and Product Candidates

    changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval or in positions, guidance or feedback communicated by the FDA or comparable foreign regulatory authorities that have a negative impact on the potential approval of tab-cel

    Was: changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval or in positions, guidance or feedback communicated by the FDA or comparable foreign regulatory authorities that have a negative impact on the potential approval of a product candidate

  • 27% rewrittenRisks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

    We have earned limited commercialization revenues to date. We may never achieve profitability or we may be unable to sustain profitability on a continuing basis

    Was: We have earned limited commercialization revenues to date. We may never achieve profitability

  • 27% rewrittenRisks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

    We have incurred substantial losses since our inception and anticipate we will continue to incur substantial losses for the foreseeable future

    Was: We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial losses for the foreseeable future

  • 23% rewrittenRisks Related to Our Intellectual Property

    We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could lose the ability to continue the development and potential commercialization of one or more of our product candidates

  • 22% rewrittenRisks Related to Ownership of Our Common Stock

    The actual or perceived failure by us, our customers, or vendors to comply with increasingly stringent laws, regulations and contractual obligations relating to privacy, data protection, and data security could harm our reputation, and subject us to significant fines and liability

  • 21% rewrittenRisks Related to Ownership of Our Common Stock

    Our workforce reductions may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business

All 80 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Results, Capital Needs, and Review of Strategic Alternatives

  1. 01Our activities to review and pursue strategic alternatives may not result in a strategic transaction, and even if we do consummate a strategic transaction, there is no assurance that it will deliver the benefits we expect or enhance stockholder value34% rewritten
  2. 02the possibility of future litigation
  3. 03We have incurred substantial losses since our inception and anticipate we will continue to incur substantial losses for the foreseeable future27% rewritten
  4. 04We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability
  5. 05We have earned limited commercialization revenues to date. We may never achieve profitability or we may be unable to sustain profitability on a continuing basis27% rewritten
  6. 06protect our rights in our intellectual property and regulatory protections portfolioNew
  7. 07the emergence of competing technologies or other adverse market developments55% rewritten
  8. 08Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on terms that are unfavorable to us

Risks Related to the Development of Our Product and Product Candidates

  1. 09We have one approved product, Ebvallo, which is currently approved in the European Economic Area (EEA), the UK and Switzerland. If we or our collaborators are unable to successfully develop, manufacture and commercialize tab-cel or experience significant delays in doing so, our business may be materially harmedNew
  2. 10maintaining and growing an organization of scientists and functional experts who can develop our products and technology100% rewritten
  3. 11Our future success is dependent on the marketing authorization of tab-cel33% rewritten
  4. 12changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval or in positions, guidance or feedback communicated by the FDA or comparable foreign regulatory authorities that have a negative impact on the potential approval of tab-cel30% rewritten
  5. 13Our T-cell immunotherapy product and product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or our inability to achieve regulatory approval, commercialize or secure payor coverage of our product candidates
  6. 14developing therapies for types of diseases beyond those initially addressed by our current product and product candidates
  7. 15The results of preclinical studies or earlier clinical studies are not necessarily predictive of future results. Our existing product candidates may not receive regulatory approval
  8. 16Clinical drug development involves a lengthy and expensive process with an uncertain outcome44% rewritten
  9. 17changes in governmental regulations or administrative actions or lack of adequate funding to continue a clinical study
  10. 18disruptions caused by man-made or natural disasters or public health pandemics or epidemics, including, for example, the COVID-19 pandemic
  11. 19our reputation may suffer
  12. 20The market opportunities for our product and product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small
  13. 21We may not be able to obtain or maintain orphan drug exclusivity for our product candidates32% rewritten
  14. 22BTD by the FDA and PRIME designation by the EMA may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval
  15. 23A Fast Track designation by the FDA or other priority review program may not lead to a faster development or regulatory review, licensure process and does not increase the likelihood that our product candidates will receive marketing licensure
  16. 24Failure to obtain regulatory or payor approval in international jurisdictions would prevent our product candidates from being marketed abroad
  17. 25The proposed revision of the European legislation on pharmaceuticals, changes in governmental administration or changes in leadership at relevant agencies could lead to uncertainties over the regulatory framework that will be applicable to medicinal products in the EU and US, including orphan medicinal products
  18. 26Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties
  19. 27The occurrence of any event or penalty described above may also generate negative publicity or inhibit our ability to successfully commercialize our products
  20. 28Changes to regulations, guidelines and recommendations published by various government agencies and organizations may affect the use of our product candidates

Risks Related to Manufacturing

  1. 29We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product and product candidates
  2. 30Delays in receiving regulatory approvals for product candidates produced at our partners' CMOs’ facilities could delay our development plans and thereby limit our ability to generate revenues50% rewritten
  3. 31achieving and maintaining ongoing compliance with cGMP regulations and other requirements of the FDA, EMA or other comparable regulatory agencies
  4. 32If one or more of our partner's CMOs' facilities is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected64% rewritten
  5. 33with the necessary regulatory requirements or may require regulatory approval before selling any products manufactured at that facility. Such an event could delay our clinical studies or reduce our commercial product revenuesNew

Risks Related to Our Dependence on Third Parties

  1. 34Maintaining clinical and commercial timelines is dependent on our partner's end-to-end supply chain network to support manufacturing; if we or our partner experience problems with third party suppliers or CMOs, we or our partner may delay development and/or commercialization of our product and product candidates40% rewritten
  2. 35If we, our partner or their CMOs are not able to successfully transfer and produce comparable product and product candidates, our ability to further develop and manufacture our product and product candidates may be negatively impacted44% rewritten
  3. 36We may not realize the benefits of strategic alliances that we may form in the future or of potential future product acquisitions or licenses

Risks Related to Our Intellectual Property

  1. 37If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected
  2. 38If we are sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our or our partners’ development and commercialization efforts40% rewritten
  3. 39We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third party’s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates
  4. 40We may not be able to protect our intellectual property rights throughout the world
  5. 41We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could lose the ability to continue the development and potential commercialization of one or more of our product candidates23% rewritten
  6. 42We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business48% rewritten
  7. 43addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product and product candidatesNew
  8. 44If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be materially adversely affected and our business could be harmed

Risks Related to Commercialization of Our Product and Product Candidates

  1. 45Our commercial success depends upon developing a clearly differentiated product and attaining significant market acceptance of our product and product candidates, if approved, among physicians, patients, healthcare payors and the medical community, including hospitals and outpatient clinics
  2. 46Our or our partner's ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations
  3. 47Current and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of our product candidates and affect the prices for our product and product candidates73% rewritten
  4. 48there may be additional challenges and/or amendments to the ACA. It is unclear how future litigation and the healthcare reform measures of future presidential administrations will impact the ACA and our businessNew
  5. 49The current presidential administration has also signaled its intent to pursue healthcare reform measures, includingNew
  6. 50Price controls may be imposed in foreign markets, which may adversely affect our future profitability
  7. 51We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
  8. 52We are subject to certain contractual obligations under our royalty financing agreement with HealthCare Royalty Partners and may be subject to claims for damages if we fail to fulfill these obligations
  9. 53We expect the product candidates we develop will be regulated as biological products (biologics) and therefore they may be subject to competition sooner than anticipated
  10. 54If we are unable to enter into agreements with third parties to market and sell our product and product candidates, we may be unable to generate any revenue from the sale of our products
  11. 55We may encounter difficulties in managing our growth, including with respect to our employee base, and managing our operations successfully
  12. 56expanding our facilities

Risks Related to Ownership of Our Common Stock

  1. 57Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance
  2. 58the other risks described in this “Risk Factors” section
  3. 59Our principal stockholders own a significant percentage of our stock and will be able to exert significant control or significant influence over matters subject to stockholder approval
  4. 60Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall
  5. 61We have incurred and will continue to incur increased costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs32% rewritten
  6. 62reliability of our financial reporting and the preparation of financial statements for external purposes in accordance withNew
  7. 63Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of potential gain for our stockholders
  8. 64Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
  9. 65Some terms of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management
  10. 66Any of the factors listed above may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management32% rewritten
  11. 67claims arising under the Securities Act and, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities ActNew
  12. 68We qualify as a “smaller reporting company” and a “non-accelerated filer,” and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to such companies could make our common shares less attractive to investors
  13. 69If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
  14. 70Our future success depends on our ability to retain and motivate our executive officers and qualified personnel
  15. 71Our workforce reductions may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business21% rewritten
  16. 72Our relationships with customers and third party payors will be subject to applicable anti-kickback, fraud and abuse, privacy and other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings
  17. 73Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation
  18. 74Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
  19. 75the inability to commercialize any products that we may develop
  20. 76The actual or perceived failure by us, our customers, or vendors to comply with increasingly stringent laws, regulations and contractual obligations relating to privacy, data protection, and data security could harm our reputation, and subject us to significant fines and liability22% rewritten
  21. 77Changes in tax laws or regulations that are applied adversely to us or our customers may have an adverse effect on our business, cash flows, financial condition or results of operations
  22. 78Our ability to use net operating loss carryforwards and certain tax assets to offset future taxable income or taxes may be subject to certain limitations
  23. 79Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses
  24. 80The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities51% rewritten

Other Atara Biotherapeutics 10-Ks

  • FY2024 10-K risk factors
    84 risks

    The company relies heavily on a single approved product, partnerships, and additional capital to survive ongoing losses and workforce reductions.

    Filed Mar 07, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.